Please assess the completion status of the following clinical trial:

Trial Title: Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~Patients eligible for inclusion in the trial must fulfil all of the following criteria:~* Male or female subjects aged 15 years of age or above, regardless of HIV status;~* Microbiological test (molecular or phenotypic) confirming presence of M. tuberculosis;~* Resistant to at least rifampicin by either molecular or phenotypic drug susceptibility test;~* Completed informed consent form (ICF);~Exclusion criteria:~Patients will not be eligible for inclusion in the trial if they meet any of the following criteria:~* Known allergies, hypersensitivity, or intolerance to any of the study drugs;~* Pregnant or breast-feeding; or unwilling to use appropriate contraceptive measures~* Liver enzymes \>3 times the upper limit of normal (AST or ALT);~* Any condition (social or medical) which, in the opinion of the investigator, would make study participation unsafe;~* Taking any medications contraindicated with the medicines in the trial;~* QTcF \> 450ms;~* One or more risk factors for QT prolongation (excluding age and gender) or other uncorrected risk factors for TdP;~* History of cardiac disease, syncopal episodes, symptomatic or asymptomatic arrhythmias (with the exception of sinus arrhythmia);~* Any baseline biochemical laboratory value consistent with Grade 4 toxicity.~* Moribund~* Known resistance to bedaquiline, pretomanid, delamanid or linezolid.~* Prior use of bedaquiline and/or pretomanid and/or linezolid and/or delamanid for one or more months.~* Patients not eligible to start a new course of MDR-TB/XDR-TB treatment according to local protocol, including but not limited to:~  * currently on MDR-TB treatment for more than 2 weeks (and not failing)~ * unstable address~ * loss to follow-up in previous treatment with no change in circumstance and motivation.~* Tuberculous meningoencephalitis, brain abscesses, osteomyelitis or arthritis.~PKPD inclusion/exclusion:~* Adult patients (aged 18 years or above) recruited into the investigational arms of the TB-PRACTECAL trial in the approved sites.~* Willing to sign the sub-study informed consent form after agreeing to the additional blood draws.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen 1 (Type: EXPERIMENTAL): Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
- Regimen 2 (Type: EXPERIMENTAL): Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
- Regimen 3 (Type: EXPERIMENTAL): Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
- Control Regimen (Type: ACTIVE_COMPARATOR): Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.

Based on this trial design, predict the completion outcome and termination type (if applicable).